心血管中成药超说明书用药循证评价方法和程序的建立(4)
[14]Chen YL，Yao L，Xiao XJ，et al.Quality assessment of clinical guidelines in China：1993-2010[J].Chin Med J，2012，125(20)：3660-3664.
[15]Moher D，Liberati A，Tetzlaff J，et al.Preferred reporting items for systematic reviews and meta-analysis：the PRISMA statement[J].J Clin pidemiol，2009，62(10)：1006-1012.
[16]Moher D，Liberati A，Tetzlaff J，et al，The PRISMA group.系统综述和荟萃分析优先报告的条目(中文翻译)[J].中西医结合学报，2009，7(9)：889-896.
[17]Oxman AD，Schunemann HJ，Frethein A.Improving the use of research evidence in guideline development，synthesis and presentation of evidence[J].Health Res Policysyst，2006(4)：20.
[18]Gordon G，Andrew D O，Elie A，等.GRADE指南：Ⅰ.導论——GRADE证据概要表和结果总结表[J].中国循证医学杂志，2011，11(4)：437-445.
[19]Schulz KF，Chalmers I，Hayes RJ，et al.Empirical evidence of bias：dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J].JAMA，1995，273(5)：408-412.
[20]Slim K，Nini E，Forestier D，et al.Methodological index for non-randomized studies(minors)：development and validation of a new instrument[J].ANZ J Surg，2003，73(9)：712.
[21]Wells G，Shea B，O′Connell D，et al.The Newcastle-OttawaScale (NOS) for assessing the quality of nonrandomized studies inmeta-analyses[EB/OL].2011.http：//www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
[22]刘建平.传统医学证据体的构成及证据分级的建议[J].中国中西医结合杂志，2007，27(12)：1061-1062.
(2017-05-10收稿 责任编辑：徐颖), 百拇医药(刘莹 商洪才)
[15]Moher D，Liberati A，Tetzlaff J，et al.Preferred reporting items for systematic reviews and meta-analysis：the PRISMA statement[J].J Clin pidemiol，2009，62(10)：1006-1012.
[16]Moher D，Liberati A，Tetzlaff J，et al，The PRISMA group.系统综述和荟萃分析优先报告的条目(中文翻译)[J].中西医结合学报，2009，7(9)：889-896.
[17]Oxman AD，Schunemann HJ，Frethein A.Improving the use of research evidence in guideline development，synthesis and presentation of evidence[J].Health Res Policysyst，2006(4)：20.
[18]Gordon G，Andrew D O，Elie A，等.GRADE指南：Ⅰ.導论——GRADE证据概要表和结果总结表[J].中国循证医学杂志，2011，11(4)：437-445.
[19]Schulz KF，Chalmers I，Hayes RJ，et al.Empirical evidence of bias：dimensions of methodological quality associated with estimates of treatment effects in controlled trials[J].JAMA，1995，273(5)：408-412.
[20]Slim K，Nini E，Forestier D，et al.Methodological index for non-randomized studies(minors)：development and validation of a new instrument[J].ANZ J Surg，2003，73(9)：712.
[21]Wells G，Shea B，O′Connell D，et al.The Newcastle-OttawaScale (NOS) for assessing the quality of nonrandomized studies inmeta-analyses[EB/OL].2011.http：//www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
[22]刘建平.传统医学证据体的构成及证据分级的建议[J].中国中西医结合杂志，2007，27(12)：1061-1062.
(2017-05-10收稿 责任编辑：徐颖), 百拇医药(刘莹 商洪才)